title: Evaluation of Teicoplanin Trough Values After the Recommended Loading Dose in Children With Associated Safety Analysis.
abstract: This study evaluated whether the recommended teicoplanin loading dose (3 loading doses of 10 mg/kg every 12 hours) achieves a 15-30 μg/mL trough levels in 26 children (2-16 years). In addition, we examined the incidences of renal impairment and hepatic dysfunction in children treated with teicoplanin.
  
  
  
  This retrospective study was conducted between October 2008 and March 2014.
  
  
  
  The percentage of patients with a trough level <10 and <15 μg/mL were 15.4% (4/26) and 46.2% (12/26), respectively. There were significant correlations between age and concentration/cumulative loading dose (C/D) ratio (P = 0.045), serum creatinine and C/D ratio (P < 0.001) and estimated glomerular filtration rate and C/D ratio (P = 0.005). Serum creatinine was significantly lower when trough levels were <15 μg/mL compared with ≥15 μg/mL. The incidences of renal impairment and hepatic dysfunction were 2.3% and 5.8%, respectively, with no significant difference between <20 and ≥20 μg/mL trough-level groups.
  
  
  
  The recommended loading dose may be insufficient to achieve 15-30 μg/mL in children with normal renal function. In addition, the target trough level ≥20 μg/mL for deep-seated infections seems to be safe in children.
authors.affiliation: From the *Department of Pharmacy, Kyushu University Hospital, †Department of Clinical Pharmacy and Pharmaceutical care, Graduate School of Pharmaceutical Sciences, Kyushu University, and ‡Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
authors.forename: Takaaki
authors.initials: T
authors.lastname: Yamada
authors.forename: Toshio
authors.initials: T
authors.lastname: Kubota
authors.forename: Mahoro
authors.initials: M
authors.lastname: Yonezawa
authors.forename: Hisanori
authors.initials: H
authors.lastname: Nishio
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Kanno
authors.forename: Takahisa
authors.initials: T
authors.lastname: Yano
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kobayashi
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Egashira
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Takada
authors.forename: Toshiro
authors.initials: T
authors.lastname: Hara
authors.forename: Satohiro
authors.initials: S
authors.lastname: Masuda
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D002648:Child; D002675:Child, Preschool; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D017334:Teicoplanin / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D000900:Anti-Bacterial Agents; D017334:Teicoplanin